SCHEMBL12414664

SCHEMBL12414664

CC(C)c1ncc(CN2CCCC2=O)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.43
PIK3CD O00329 1/20 0.41
CYP11B2 P19099 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PANK3 Q9H999 1/20 0.39
GRIA2 P42262 4/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2C9 P11712 2/20 0.38
LTA4H P09960 1/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38
HRH3 Q9Y5N1 1/20 0.37
BDKRB1 P46663 1/20 0.37
CDC7 O00311 1/20 0.37
PLK4 O00444 1/20 0.37
AURKA O14965 1/20 0.37
MAPK13 O15264 1/20 0.37
PDPK1 O15530 1/20 0.37
DYRK3 O43781 1/20 0.37
PRKD3 O94806 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12507071 0.83 MAPK1 (0.43) ACACBPIK3CDCYP11B2L3MBTL1GRIA2
SCHEMBL12414652 0.75 HTR6 (0.40) CYP11B2CYP1A2CYP2C9KMT2AHRH3
SCHEMBL16897792 0.71 MAPK1 (0.55) ACACBL3MBTL1GRIA2CYP1A2CYP2C9
SCHEMBL12414662 0.71 CYP19A1 (0.37) PANK3
SCHEMBL13853395 0.70 L3MBTL1 (0.53) ACACBL3MBTL1GRIA2CYP1A2CYP2C9
SCHEMBL21105492 0.69 PANK3 (0.38) PANK3CYP1A2PARP1
SCHEMBL24713153 0.69 L3MBTL1 (0.59) ACACBPIK3CDL3MBTL1GRIA2CYP1A2
SCHEMBL22330251 0.69 L3MBTL1 (0.55) ACACBL3MBTL1GRIA2CYP1A2CYP2C9
SCHEMBL22324939 0.69 L3MBTL1 (0.51) ACACBL3MBTL1GRIA2CYP1A2CYP2C9
SCHEMBL1424043 0.69 L3MBTL1 (0.51) ACACBL3MBTL1GRIA2CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293729-B2 Compounds, pharmaceutical composition and methods relating thereto BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-23 US disclosed
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO MC2R, REN, CYP11B2 ACACB 1028/4885PIK3CD 1258/4885CYP11B2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.